BCG+MMC trial: Adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: A randomised phase III trial (ANZUP 1301)

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Hayne, Dickon ^a,b,c   Stockler, Martin ^a,d   McCombie, Steve P ^a,b,c   Chalasani, Venu ^a,d,e   Long, Anne ^a,d   Martin, Andrew ^a,d   Sengupta, Shomik ^a,f,g,h   Davis, Ian D ^a,i  

^a Australian and New Zealand Urogenital and Prostate Cancer Trials Group   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c FIONA STANLEY HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e HORNSBY KU RING GAI HOSPITAL   (Australia)

^f AUSTIN HEALTH   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h AUSTIN HOSPITAL   (Australia)

ⁱ MONASH UNIVERSITY   (Australia)

Author keywords

BCG; Bladder cancer; Intravesical; Mitomycin; Transitional cell carcinoma

Indexed keywords

BCG VACCINE; MITOMYCIN; ANTINEOPLASTIC ANTIBIOTIC;

ADD ON THERAPY; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTECTOMY; DISEASE ACTIVITY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; EXPERIMENTAL THERAPY; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; MAINTENANCE THERAPY; MALE; META ANALYSIS (TOPIC); MULTICENTER STUDY; NON MUSCLE INVASIVE BLADDER CANCER; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; CANCER STAGING; CLINICAL PROTOCOL; CLINICAL TRIAL; INTRAVESICAL DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TUMOR INVASION; URINARY BLADDER NEOPLASMS;

ADMINISTRATION, INTRAVESICAL; ANTIBIOTICS, ANTINEOPLASTIC; BCG VACCINE; CLINICAL PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MITOMYCIN; NEOPLASM INVASIVENESS; NEOPLASM STAGING; URINARY BLADDER NEOPLASMS;

EID: 85019220664     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1431-6     Document Type: Article

References (20)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. UK CR. Bladder cancer statistics. [cited 2014 16/04/2014]; Available from: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/bladder/
3. Australian Institute of H, Welfare. Cancer survival and prevalence in Australia: period estimates from 1982 to 2010. Asia Pac J Clin Oncol. 2013;9:29-39.
4. Babjuk M, Burger M, Zigeuner R, Shariat S, Van Rhijn B, Compérat E, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). 2013.
5. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466-75. discussion 75-7.
6. SEER Cancer Statistics Factsheets: Bladder Cancer. National Cancer Institute. [cited 2014 16/04/2014]; Available from: http://seer.cancer.gov/statfacts/html/urinb.html
7. Shelley MD, Kynaston H, Court J, Wilt TJ, Coles B, Burgon K, et al. A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int. 2001;88:209-16.
8. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168:1964-70.
9. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007;178:2314-30.
10. Zlotta AR, Fleshner NE, Jewett MA. The management of BCG failure in non-muscle-invasive bladder cancer: an update. Canadian Urological Association journal = Journal de l'Association des urologues du Canada. 2009;3:S199-205.
11. Tolley DA, Parmar MK, Grigor KM, Lallemand G, Benyon LL, Fellows J, et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol. 1996;155:1233-8.
12. Pawinski A, Sylvester R, Kurth KH, Bouffioux C, van der Meijden A, Parmar MK, K, et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol. 1996;156:1934-40. discussion 40-1.
13. Houghton BB, Chalasani V, Hayne D, Grimison P, Brown CS, Patel M, et al. Intravesical chemotherapy plus bacille Calmette-Guerin in non-muscle invasive bladder cancer: a systematic review with meta-analysis. BJU Int. 2013;111:977-83.
14. Di Stasi SM, Giannantoni A, Giurioli A, Valenti M, Zampa G, Storti L, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 2006;7:43-51.
15. Hayne D, Stockler M, Ives A, Houghton BB, Braganza P, Chalasani V, et al. Sequential BCG and mitomycin intravesical therapy versus BCG alone for high-risk non-muscle invasive bladder cancer (NMIBC): pilot study and proposal for a 2-stage randomised phase III trial. BJU Int. 2011;107:25.
16. Barry MJ, Fowler Jr FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148:1549-57. discussion 64.
17. O'Leary MP, Sant GR, Fowler Jr FJ, Whitmore KE, Spolarich-Kroll J. The interstitial cystitis symptom index and problem index. Urology. 1997;49:58-63.
18. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-55.
19. EORTC Quality of Life Module for Bladder Cancer - Urinary Symptoms. [cited 21 March, 2011]; Available from: http://groups.eortc.be/qol/bladder-cancer-eortc-qlq-bls24-eortc-qlq-blm30
20. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-76.